| pubmed-article:10037196 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0740457 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0079722 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0011306 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0376659 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0967777 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C1515877 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C0449450 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:10037196 | lifeskim:mentions | umls-concept:C1548795 | lld:lifeskim |
| pubmed-article:10037196 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10037196 | pubmed:dateCreated | 1999-4-29 | lld:pubmed |
| pubmed-article:10037196 | pubmed:abstractText | The clinical impact of dendritic cells (DCs) in the treatment of human cancer depends on their unique role as the most potent antigen-presenting cells that are capable of priming an antitumor T-cell response. Here, we demonstrate that functional DCs can be generated from peripheral blood of patients with metastatic renal cell carcinoma (RCC) by culture of monocytes/macrophages (CD14+) in autologous serum containing medium (RPMI) in the presence of granulocyte macrophage colony-stimulating factor and interleukin (IL) 4. For testing the capability of RCC-antigen uptake and processing, we loaded these DCs with autologous tumor lysate (TuLy) using liposomes, after which cytometric analysis of the DCs revealed a markedly increased expression of HLA class I antigen and a persistent high expression of class II. The immunogenicity of DC-TuLy was further tested in cultures of renal tumor infiltrating lymphocytes (TILs) cultured in low-dose IL-2 (20 Biologic Response Modifier Program units/ml). A synergistic effect of DC-TuLy and IL-2 in stimulating a T cell-dependent immune response was demonstrated by: (a) the increase of growth expansion of TILs (9.4-14.3-fold; day 21); (b) the up-regulation of the CD3+ CD56- TcR+ (both CD4+ and CD8+) cell population; (c) the augmentation of T cell-restricted autologous tumor lysis; and (d) the enhancement of IFN-gamma, tumor necrosis factor-alpha, granulocyte macrophage colony-stimulating factor, and IL-6 mRNA expression by TILs. Taken together, these data implicate that DC-TuLy can activate immunosuppressed TIL via an induction of enhanced antitumor CTL responses associated with production of Thl cells. This indicates a potential role of DC-TuLy vaccines for induction of active immunity in patients with advanced RCC. | lld:pubmed |
| pubmed-article:10037196 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10037196 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10037196 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10037196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10037196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10037196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10037196 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10037196 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10037196 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:FrankJJ | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:RothM DMD | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:deKernionJJ | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:BelldegrunAA | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:TsoC LCL | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:KabooRR | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:FiglinRR | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:GitlitzBB | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:HinkelAA | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:KiertscherSS | lld:pubmed |
| pubmed-article:10037196 | pubmed:author | pubmed-author:MuldersPP | lld:pubmed |
| pubmed-article:10037196 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10037196 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:10037196 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10037196 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10037196 | pubmed:pagination | 445-54 | lld:pubmed |
| pubmed-article:10037196 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:meshHeading | pubmed-meshheading:10037196... | lld:pubmed |
| pubmed-article:10037196 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10037196 | pubmed:articleTitle | Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. | lld:pubmed |
| pubmed-article:10037196 | pubmed:affiliation | University of California at Los Angeles, Department of Urology, 90095-1738, USA. | lld:pubmed |
| pubmed-article:10037196 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10037196 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10037196 | lld:pubmed |
